Tag: threaten

Categories
Health

Sacklers Threaten to Pull Out of Opioid Settlement With out Broad Authorized Immunity

Sacklers Threaten to Pull Out of Opioid Settlement Without Broad Legal Immunity

At least 2,700 lawsuits and hundreds of thousands of lawsuits have been registered against Purdue, beginning in 2014 when the opioid epidemic peaked. Plaintiffs span a broad spectrum including 48 states, local governments, tribes, hospitals, individuals and caregivers of infants born with symptoms of withdrawal from opioids, all of whom are devastated and financially exhausted from opioids.

In the last few years, more and more cases, individual sackers have been named themselves.

Nearly two years ago, Purdue filed for bankruptcy restructuring that automatically suspended those lawsuits. However, the Sacklers themselves did not file for bankruptcy, despite insisting that they too benefit from their company’s expected indemnities.

The issue of releases for the Sacklers and other third parties is at the center of opposition to the bankruptcy scheme that is now being pursued by nine states, including Maryland, Washington and Connecticut. The District of Columbia, the Federal Department of Justice and the U.S. Trustee, a Department of Justice program that monitors bankruptcy cases, as well as several Canadian local governments and First Nations have joined in the opposition.

Under applicable law of the Second Circuit Court of Appeals, where the Judge Drain Court is located, the judge may grant exemptions to the Sacklers and other third parties who have not filed for bankruptcy. But, by and large, the issue is unresolved.

Other federal districts prohibit it. The issue has been taken up by members of Congress and could well lead to an appeal by the opponents if Judge Drain approves the plan. The pounding questions of contradicting attorneys so far should not only raise questions about the plan, but lay a foundation for such appeals.

Alain Delaquérière contributed to the research.

Categories
Politics

Moderates Threaten Stalemate Over Price range Vote and Infrastructure

Moderates Threaten Stalemate Over Budget Vote and Infrastructure

WASHINGTON – Nine moderate House Democrats told Spokeswoman Nancy Pelosi on Friday that they will not vote for a budget decision that will pave the way for a $ 3.5 trillion social package to be passed later this year, until one dated Senate-approved infrastructure law passed the house and is legally signed.

The commitment in a letter early Friday is a major rift that threatens the carefully choreographed, two-pronged efforts of the Democrats in Congress and the Biden administration, both a trillion-dollar non-party infrastructure deal and an even more ambitious – but partisan one – To adopt the contract. social policy measure. The nine members of the House of Representatives are more than enough to block scrutiny of the draft budget in a house where Democrats have a three-seat majority.

The Senate passed the infrastructure bill on Tuesday with 69 votes, including 19 Republicans. It then approved a $ 3.5 trillion budget resolution in a party line vote early Wednesday that would allow Democrats in both houses to pass the social policy bill this fall without fear of a Republican Senate filibuster say goodbye.

To reassure more liberal Democrats who are more interested in the social policy law, Ms. Pelosi promised that she would not put the infrastructure law to the vote in the House of Representatives until the Senate passes the social policy law.

Given the 50-50 partisan split in the Senate, this may not happen well into the fall. And moderate Democrats in the House of Representatives say delaying an infrastructure vote runs the risk of unforeseen events derailing them.

“With the livelihoods of hard-working American families at stake, we simply cannot afford months of unnecessary delays and risk wasting this century’s bipartisan infrastructure package,” the letter submitted to and submitted to the New York Times reads Josh Gottheimer, Democrat of New Jersey, as lead author. “It’s time to shovel shovels in the ground and get people to work.”

Complicating the situation is that more than half of the nearly 100-strong Progressive Caucus in Congress take the opposite position, saying they won’t vote for the Infrastructure Bill until they have a sociopolitical measure that funds their priorities: climate change , Education, healthcare, family vacations, childcare and elderly care.

With the promised defectors from the Progressive Caucus, it appears that Ms. Pelosi is facing a stalemate as she does not have the votes to either get the infrastructure bill to President Biden’s desk or move forward the budgetary resolution needed to bring final Republican legislation forward Protect disability.

So far, most Democrats in Congress have been optimistic that both measures will find enough support.

“This is President Biden’s agenda, this is the Democrats’ agenda, this is what we walked on and what we need to deliver,” Minnesota Rep. Ilhan Omar, a Progressive Caucus leader, said of the social policy bill. “It is important for us not to miss the target and I see no conflict.”

But their moderate counterparts do. “We will not consider voting for a budget decision until the bipartisan Infrastructure Investment and Jobs Bill is passed by the House of Representatives and comes into effect,” they wrote.

The draft letter was signed by Mr. Gottheimer and representatives Filemon Vela from Texas, Henry Cuellar from Texas, Ed Case from Hawaii, Kurt Schrader from Oregon, Carolyn Bourdeaux from Georgia, Jared Golden from Maine, Vicente Gonzalez from Texas and Jim Costa from California.

Categories
Politics

Janet Yellen Warns That Coronavirus Variants Threaten World Restoration

Janet Yellen Warns That Coronavirus Variants Threaten Global Recovery

VENICE – Treasury Secretary Janet L. Yellen said Sunday she was concerned that coronavirus variants could slow global economic recovery and called for urgent efforts to accelerate vaccine use around the world.

Your comments on the conclusion of a meeting of Finance Ministers of the Group of 20 Nations came when the highly contagious Delta variant of the coronavirus triggered outbreaks among unvaccinated populations in countries like Australia, Indonesia, Malaysia and Portugal. Delta is now also the dominant variant in the USA.

“We are very concerned about the Delta variant and other variants that are emerging that could threaten recovery,” said Ms. Yellen. “We are a networked global economy. What happens in any part of the world affects all other countries. “

Many cities and countries have begun declaring victory over the pandemic, easing restrictions and returning to normal life. But Ms. Yellen warned that the public health crisis was not over.

She said the world’s top economic officials spent much of the weekend in Venice discussing how they could improve vaccine distribution with the goal of vaccinating 70 percent of the world by next year. Ms. Yellen noted that many countries have successfully funded vaccine purchases but lack the logistics to get them into people’s arms.

“We have to do more and be more effective,” she said.

The proliferation of variants has begun to dampen optimism about the course of the recovery.

Capital Economics analysts announced this week that they intend to cut their economic growth outlook for the year to below 6 percent.

The proliferation of new varieties of coronavirus has “raised doubts about the pace of real economic growth in the second half of this year and beyond,” wrote Paul Ashworth, chief economist for North America at Capital Economics, in a research note.

The International Monetary Fund said it was sticking to its 6 percent global growth forecast this year, but warned that growth would be stifled in developing countries where infection rates are skyrocketing.

“The divergence between economies is worsening,” said IMF Managing Director Kristalina Georgieva on Saturday. “Essentially, the world is facing a two-pronged recovery.”

Some finance ministers also raised concerns over the weekend that variants and slow vaccine uptake could turn the recovery on its head. This concern was highlighted in the Group’s joint statement as a downside risk to the world economy.

“The only hurdle on the way to a quick, solid economic recovery is the risk of a new wave of pandemics,” said French Finance Minister Bruno Le Maire. “We all need to improve our vaccination performance.”

The IMF Executive Board last week approved a plan to provide $ 650 billion in reserve funds that countries could use to buy vaccines and fund health initiatives.

Ms. Yellen said she urged her group of 20 colleagues to expedite the “fair” delivery and distribution of vaccines, diagnostics and therapeutics to ensure that low- and middle-income countries could fight the virus flare-up.

Policy makers at the weekend’s meeting also spent time focusing on new investments in preparation for future pandemics. Ms. Yellen said that while this is important, more needs to be done in the short term.

“Variants certainly pose a threat to the entire globe,” she said.

Categories
Politics

Biden reiterates assist for bipartisan infrastructure plan, didn’t threaten veto

Biden reiterates support for bipartisan infrastructure plan, did not threaten veto

President Joe Biden on Saturday said he doesn’t plan to veto a bipartisan infrastructure bill if it comes without a reconciliation package, walking back a declaration last week that he would refuse to sign it unless the two bills came in tandem.

The comment angered some Republican lawmakers, including Senate Minority Leader Mitch McConnell, who said the president was threatening to veto the bipartisan deal in remarks on the Senate floor on Thursday.

“That statement understandably upset some Republicans, who do not see the two plans as linked,” the president said in a statement.

“My comments also created the impression that I was issuing a veto threat on the very plan I had just agreed to, which was certainly not my intent,” the president said.

A bipartisan group of lawmakers closed a deal on an infrastructure initiative Thursday following weeks of negotiations to craft a package that could get through Congress with Republican and Democratic support. The framework will include $579 billion in new spending to improve the country’s roads, bridges and broadband.

The second bill would include funding for Democrat-backed issues like climate change, childcare, health care and education, issues that administration officials have called “human infrastructure.” It would be passed through a Senate process called reconciliation, which doesn’t require Republican votes.

House Speaker Nancy Pelosi, D-Calif., on Thursday morning said the House would not take up either piece of legislation until both are passed through the Senate. Democrats can’t lose a single vote on a reconciliation bill in the evenly split chamber.

Biden said he will ask Senate Majority Leader Chuck Schumer, D-N.Y., to schedule the infrastructure plan and the reconciliation bill for action in the Senate and expects them both to go to the House.

“Ultimately, I am confident that Congress will get both to my desk, so I can sign each bill promptly,” Biden said.

Read the president’s full statement here:

On Thursday, I reached a historic agreement with a bipartisan group of Senators on a $1.2 trillion plan to transform our physical infrastructure. The plan would make the largest investment in infrastructure in history, the biggest investment in rail since the creation of Amtrak, and the largest investment in transit ever. It would fix roads and bridges, make critical investments in our clean energy future, and help this country compete with China and other economic rivals. It would replace lead water pipes in our schools and houses, and connect every American to high-speed internet. It would create millions of high-paying jobs that could not be outsourced.

In the days since, the primary focus in Washington has not been about the Plan’s scope, scale or provisions—but rather, how it relates to other legislation before Congress: my American Families Plan. The American Families Plan—which would make historic investments in education, health care, child care, and tax cuts for families, coupled with other investments in care for our seniors, housing, and clean energy—has broad support with the American people, but not among Republicans in Congress.

I have been clear from the start that it was my hope that the infrastructure plan could be one that Democrats and Republicans would work on together, while I would seek to pass my Families Plan and other provisions through the process known as reconciliation. There has been no doubt or ambiguity about my intention to proceed this way.

At a press conference after announcing the bipartisan agreement, I indicated that I would refuse to sign the infrastructure bill if it was sent to me without my Families Plan and other priorities, including clean energy. That statement understandably upset some Republicans, who do not see the two plans as linked; they are hoping to defeat my Families Plan—and do not want their support for the infrastructure plan to be seen as aiding passage of the Families Plan. 

My comments also created the impression that I was issuing a veto threat on the very plan I had just agreed to, which was certainly not my intent. So to be clear: our bipartisan agreement does not preclude Republicans from attempting to defeat my Families Plan; likewise, they should have no objections to my devoted efforts to pass that Families Plan and other proposals in tandem. We will let the American people—and the Congress—decide. 

The bottom line is this: I gave my word to support the Infrastructure Plan, and that’s what I intend to do. I intend to pursue the passage of that plan, which Democrats and Republicans agreed to on Thursday, with vigor. It would be good for the economy, good for our country, good for our people. I fully stand behind it without reservation or hesitation. 

Some other Democrats have said they might oppose the Infrastructure Plan because it omits items they think are important: that is a mistake, in my view. Some Republicans now say that they might oppose the infrastructure plan because I am also trying to pass the American Families Plan: that is also a mistake, in my view. I intend to work hard to get both of them passed, because our country needs both—and I ran a winning campaign for President that promised to deliver on both. No one should be surprised that that is precisely what I am doing. 

I will ask Leader Schumer to schedule both the infrastructure plan and the reconciliation bill for action in the Senate. I expect both to go to the House, where I will work with Speaker Pelosi on the path forward after Senate action. Ultimately, I am confident that Congress will get both to my desk, so I can sign each bill promptly.

Categories
Health

Virus Variants Threaten to Draw Out the Pandemic, Scientists Say

Virus Variants Threaten to Draw Out the Pandemic, Scientists Say

Seit Wochen ist die Stimmung in weiten Teilen der USA lebhaft. Fälle, Krankenhausaufenthalte und Todesfälle durch das Coronavirus sind stark von ihren Höchstständen gefallen, und täglich werden Millionen von Menschen neu geimpft. Restaurants, Geschäfte und Schulen haben wieder geöffnet. Einige Staaten, wie Texas und Florida, haben die Vorsichtsmaßnahmen ganz aufgegeben.

Auf messbare Weise gewinnen Amerikaner den Krieg gegen das Coronavirus. Leistungsstarke Impfstoffe und ein beschleunigter Rollout garantieren beinahe eine Rückkehr zur Normalität – zu Gartengrills, Sommercamps und Übernachtungen.

Es wird jedoch zunehmend klarer, dass die nächsten Monate schmerzhaft sein werden. Sogenannte Varianten breiten sich aus und tragen Mutationen, die das Coronavirus sowohl ansteckender als auch in einigen Fällen tödlicher machen.

Selbst als Ende letzten Jahres Impfstoffe zugelassen wurden, die einen Weg zum Ende der Pandemie aufzeigten, waren Varianten Großbritanniens, Südafrikas und Brasiliens betroffen. Es sind immer wieder neue Varianten aufgetaucht – in Kalifornien in einer Woche, in New York und Oregon in der nächsten. Diese neuen Versionen des Coronavirus drohen, ein Ende der Pandemie zu verschieben, wenn sie Wurzeln schlagen.

Im Moment scheinen die meisten Impfstoffe gegen die Varianten wirksam zu sein. Die Beamten des öffentlichen Gesundheitswesens sind jedoch zutiefst besorgt darüber, dass künftige Iterationen des Virus möglicherweise resistenter gegen die Immunantwort sind und die Amerikaner sich für regelmäßige Auffrischungsrunden oder sogar neue Impfstoffe anstellen müssen.

“Wir haben keine Evolution auf unserer Seite”, sagte Devi Sridhar, Professor für öffentliche Gesundheit an der Universität von Edinburgh in Schottland. “Dieser Erreger scheint sich immer so zu verändern, dass es uns schwerer fällt, ihn zu unterdrücken.”

Gesundheitsbeamte erkennen die dringende Notwendigkeit an, diese neuen Viren zu verfolgen, wenn sie durch die Vereinigten Staaten kriechen. Bereits jetzt steigt B.1.1.7, die hoch ansteckende Variante, die Großbritannien ummauerte und in Kontinentaleuropa Chaos anrichtet, in den Vereinigten Staaten exponentiell an.

Begrenzte Gentests haben mehr als 12.500 Fälle ergeben, viele davon in Florida und Michigan. Ab dem 13. März machte die Variante landesweit etwa 27 Prozent der Neuerkrankungen aus, gegenüber nur 1 Prozent Anfang Februar.

Die Regierung von Biden hat eine „Anzahlung“ in Höhe von 200 Millionen US-Dollar zugesagt, um die Überwachung zu beschleunigen. Diese Infusion soll es ermöglichen, wöchentlich 25.000 Patientenproben auf Virusvarianten zu analysieren. Es ist ein ehrgeiziges Ziel: Das Land sequenzierte im Dezember nur wenige hundert Proben pro Woche und skalierte ab dem 27. März auf etwa 9.000 pro Woche.

Bis vor kurzem wurde der Anstieg von B.1.1.7 durch sinkende Infektionsraten insgesamt getarnt, was die Amerikaner in ein falsches Sicherheitsgefühl wiegte und zu vorzeitig gelockerten Beschränkungen führte, sagen Forscher.

“Der beste Weg, über B.1.1.7 und andere Varianten nachzudenken, besteht darin, sie als separate Epidemien zu behandeln”, sagte Sebastian Funk, Professor für Dynamik von Infektionskrankheiten an der London School of Hygiene and Tropical Medicine. “Wir verdunkeln die Sicht wirklich, indem wir sie alle addieren, um eine Gesamtzahl von Fällen zu erhalten.”

Andere in Südafrika und Brasilien identifizierte Varianten sowie einige erstmals in den USA beobachtete Virusversionen verbreiteten sich langsamer. Aber auch sie sind besorgniserregend, weil sie eine Mutation enthalten, die die Wirksamkeit der Impfstoffe verringert. Erst diese Woche erzwang ein Ausbruch von P.1, der Variante, die Brasilien zerschmetterte, die Schließung des Skigebiets Whistler Blackcomb in British Columbia.

Die Welt befindet sich in einem Sprint zwischen Impfstoffen und Varianten, und die Schüsse werden schließlich gewinnen, sagen Wissenschaftler. Da sich das Coronavirus bei jeder Infektion weiterentwickeln kann, müssen Impfungen in den USA und anderswo so schnell wie möglich durchgeführt werden.

Die Infektionen nehmen wieder zu, was durch B.1.1.7 und andere Varianten in ungewissem Maße bedingt ist. Anfang dieser Woche bat Dr. Rochelle Walensky, Direktorin der Zentren für die Kontrolle und Prävention von Krankheiten, die Amerikaner, weiterhin Maskierung und soziale Distanzierung zu üben, und sagte, sie habe das Gefühl eines „bevorstehenden Untergangs“.

“Wir dürfen uns so sehr freuen – so viel Versprechen und Potenzial, wo wir sind, und so viel Grund zur Hoffnung”, sagte sie. “Aber im Moment habe ich Angst.”

Das Coronavirus sollte sich nur langsam verändern. Wie alle Viren würde es Mutationen aufnehmen und sich zu Tausenden von Varianten entwickeln, sagten Wissenschaftler zu Beginn der Pandemie. Aber es würde sich jahrelang nicht wesentlich ändern – ein dummes Virus, wie manche es nannten.

Der Erreger widersetzte sich diesen Vorhersagen. “Wir haben erwartet, dass sich das Virus ändert”, sagte Dr. Michael Diamond, ein viraler Immunologe an der Washington University in St. Louis. “Wir haben nicht genau erwartet, wie schnell es passieren wird.”

Eine Variante ist nur dann von Belang, wenn sie ansteckender ist, schwerere Krankheiten verursacht oder die Immunantwort abschwächt. Die in Großbritannien, Südafrika, Brasilien und Kalifornien identifizierten Varianten erfüllen alle die Kriterien.

B.1.1.7, das als erstes allgemein bekannt wurde, ist nach jüngsten Schätzungen etwa 60 Prozent ansteckender und 67 Prozent tödlicher als die ursprüngliche Form des Virus.

Aktualisiert

3. April 2021, 15:04 Uhr ET

Die Variante unterscheidet sich nicht von der ursprünglichen, wie sie sich verbreitet, aber infizierte Menschen scheinen mehr und länger vom Virus zu tragen, sagte Katrina Lythgoe, eine Evolutionsbiologin an der Universität von Oxford. “Sie sind für mehr Tage ansteckender”, sagte sie.

B.1.1.7 ist so ansteckend, dass es Großbritannien erst nach fast drei Monaten strenger Anweisungen für den Aufenthalt zu Hause und einem aggressiven Impfprogramm gelungen ist, Infektionen zu bekämpfen. Trotzdem fielen die Fälle viel langsamer als bei einer ähnlichen Sperrung im März und April.

In Kontinentaleuropa bildete sich monatelang eine Welle von B.1.1.7-Fällen, die unter einer stetigen Abwanderung von Infektionen meist unbemerkt blieb. Die Variantenwelle erklimmt jetzt.

Polens Rate an täglichen Neuerkrankungen hat sich seit Mitte Februar verfünffacht, was die Schließung der meisten öffentlichen Veranstaltungsorte erzwingt. Deutschlands hat sich verdoppelt und ein Verbot von nächtlichen Versammlungen in Berlin ausgelöst.

In Frankreich, wo B.1.1.7 drei Viertel der Neuinfektionen verursacht, mussten einige Krankenhäuser Coronavirus-Patienten nach Belgien bringen, um Betten freizugeben. In Europa sterben jeden Tag ungefähr so ​​viele Menschen an Covid-19 wie vor einem Jahr.

Zu lange ignorierten Regierungsbeamte die Bedrohung. “Fallplateaus können die Entstehung neuer Varianten verbergen”, sagte Carl Pearson, ein wissenschaftlicher Mitarbeiter an der London School of Hygiene and Tropical Medicine. “Und je höher diese Hochebenen sind, desto schlimmer ist das Problem.”

In den Vereinigten Staaten begannen die Coronavirus-Infektionen im Januar rapide abzunehmen, was viele Staatsoberhäupter bald dazu veranlasste, Geschäfte wieder zu eröffnen und Beschränkungen zu lockern. Wissenschaftler warnten jedoch wiederholt davor, dass der Tropfen nicht von Dauer sein würde. Nachdem die Rate Mitte März bei etwa 55.000 Fällen und 1.500 Todesfällen pro Tag ihren Tiefpunkt erreicht hatte, verzeichneten einige Bundesstaaten – insbesondere Michigan – einen Anstieg.

Seitdem sind die nationalen Zahlen stetig gestiegen. Ab Samstag lag die tägliche Zahl bei fast 69.000, und der wöchentliche Durchschnitt lag um 19 Prozent über dem Wert von zwei Wochen zuvor.

Selbst wenn die Fälle zurückgingen, stellten die Forscher die Vorstellung in Frage, dass Impfungen der Grund seien. Millionen von Amerikanern werden jeden Tag geimpft, aber selbst jetzt haben nur 31 Prozent eine Einzeldosis eines Impfstoffs erhalten, und nur 17 Prozent der Bevölkerung haben vollen Schutz, so dass eine große Mehrheit anfällig ist.

“Tatsache ist, dass wir immer noch in einer Position sind, in der wir nicht genug geimpfte Menschen haben”, sagte Kristian Andersen, Virologe bei Scripps Research in San Diego. „Und wenn wir wie Texas sagen, dass wir mit Covid-19 fertig sind, wird B.1.1.7 hereinkommen und uns daran erinnern, dass wir nicht richtig liegen. Ich habe keinen Zweifel.”

Die Variante ist besonders in Florida verbreitet, wo der Staat die Beschränkungen aufhob und zunächst keinen Anstieg verzeichnete. Beamte in anderen Staaten führten dies als Begründung für die Wiedereröffnung an. Aber jetzt steigt Floridas Infektionsrate nach oben.

Die Variante wurde möglicherweise nur durch das verdeckt, was Wissenschaftler gerne als Saisonalität bezeichnen. Infektionen der Atemwege sind in Florida im Frühjahr normalerweise selten, bemerkte Sarah Cobey, Evolutionsbiologin an der Universität von Chicago. Coronavirus-Infektionen erreichten im Sommer letzten Jahres in Florida ihren Höhepunkt, als die Hitze die Menschen in Innenräumen trieb und dies möglicherweise erneut tun wird.

“Ich glaube immer noch nicht, dass wir nicht im Wald sind”, sagte Dr. Cobey und bezog sich auf das ganze Land. “Wenn wir diesen Frühling keine weitere Welle haben, werde ich mir wirklich große Sorgen um den Herbst machen.”

Während die meisten Impfstoffe gegen B.1.1.7 wirksam sind, sind Forscher zunehmend besorgt über andere Varianten, die eine Mutation namens E484K enthalten. (Wissenschaftler bezeichnen es oft angemessen als “Eek”.)

Diese Mutation hat sich in vielen Varianten weltweit unabhängig entwickelt, was darauf hindeutet, dass sie dem Virus einen starken Überlebensvorteil bietet.

In Laborstudien scheinen die Impfstoffe Pfizer-BioNTech und Moderna gegen B.1.351, die in Südafrika identifizierte Variante, etwas weniger wirksam zu sein. Diese Variante enthält die Eek-Mutation, die es dem Virus zu ermöglichen scheint, die Immunantwort des Körpers teilweise zu umgehen. Die von Johnson & Johnson, AstraZeneca und Novavax hergestellten Impfstoffe waren gegen B.1.351 noch weniger wirksam.

“Ich denke, für die nächsten ein oder zwei Jahre wird E484K die am meisten besorgniserregende Mutation sein”, sagte Jesse Bloom, Evolutionsbiologe am Fred Hutchinson Cancer Research Center in Seattle.

Die Mutation verändert das sogenannte Spike-Protein, das auf der Oberfläche des Coronavirus sitzt, geringfügig, was es für Antikörper nur ein wenig schwieriger macht, sich an den Eindringling zu binden und ihn zu zerstören.

Die gute Nachricht ist, dass das Virus nur ein paar Überlebenstricks in der Tasche zu haben scheint, und das erleichtert es Wissenschaftlern, diese Abwehrkräfte zu finden und zu blockieren. “Ich fühle mich ziemlich gut bei der Tatsache, dass es nicht so viele Möglichkeiten gibt”, sagte Michel Nussenzweig, Immunologe an der Rockefeller University in New York.

Die Eek-Mutation scheint die primäre Abwehr des Virus gegen das Immunsystem zu sein. Forscher in Südafrika berichteten kürzlich, dass ein neuer Impfstoff gegen B.1.351 auch alle anderen Varianten abwehren sollte.

Pfizer, BioNTech und Moderna testen bereits neu entwickelte Booster-Shots gegen B.1.351, die gegen alle Varianten wirken sollen, von denen bekannt ist, dass sie die Immunantwort abschwächen.

Anstelle eines neuen Impfstoffs gegen Varianten könnte es für Amerikaner jedoch genauso effektiv sein, innerhalb von sechs Monaten bis zu einem Jahr eine dritte Dosis der Pfizer-BioNtech- oder Moderna-Impfstoffe zu erhalten, sagte Dr. Anthony S. Fauci, Leiter des National Institut für Allergien und Infektionskrankheiten.

Dies würde die Antikörperniveaus bei jedem Empfänger hoch halten und jede Variante überwältigen – eine praktischere Strategie als die Herstellung eines speziellen Impfstoffs für jede neue Variante, sagte er.

“Meine einzige Sorge bei der Jagd nach allen Varianten ist, dass Sie fast Whac-A-Mole spielen würden, wissen Sie, weil sie immer wieder auftauchen”, sagte Dr. Fauci.

In der einen oder anderen Form wird das neue Coronavirus bleiben, glauben viele Wissenschaftler. Im Land können mehrere Varianten gleichzeitig im Umlauf sein, wie dies bei Erkältungs-Coronaviren und Influenza der Fall ist. Um sie in Schach zu halten, ist möglicherweise ein jährlicher Schuss erforderlich, wie z. B. der Grippeimpfstoff.

Der beste Weg, um die Entstehung gefährlicher Varianten zu verhindern, besteht darin, die Fälle jetzt gering zu halten und die große Mehrheit der Welt – nicht nur die Vereinigten Staaten – so schnell wie möglich zu immunisieren. Wenn bedeutende Taschen der Welt ungeschützt bleiben, wird sich das Virus auf gefährliche neue Weise weiterentwickeln.

“Dies könnte etwas sein, mit dem wir uns noch lange befassen müssen”, sagte Rosalind Eggo, Epidemiologin an der London School of Hygiene and Tropical Medicine.

Dennoch fügte sie hinzu: “Auch wenn es sich wieder ändert, was sehr wahrscheinlich ist, sind wir in einer besseren, viel stärkeren Position als vor einem Jahr, um damit umzugehen.”

Categories
Politics

White Home so as to add AAPI liaison after Democrats threaten to dam Biden’s nominees

White House to add AAPI liaison after Democrats threaten to block Biden's nominees

Senator Tammy Duckworth, D-Ill.

Tom Williams | CQ appeal | Getty Images

The White House said it would appoint a “high-level” liaison officer for Asia Pacific islanders, an official told NBC News on Wednesday.

The announcement came after two Democratic senators, Tammy Duckworth of Illinois and Hawaiian Mazie Hirono, vowed to vote against President Joe Biden’s candidates in protest at the lack of AAPI representation in his administration.

Duckworth and Hirono later went back on the threats, saying they had received new assurances from the White House.

The dispute over AAPI’s representation in the White House comes after Biden tried to rally the American people against an increase in violence and discrimination against Asian Americans last year amid the coronavirus pandemic.

“The president has made it clear that his administration will reflect the diversity of the country. That was and is our goal,” White House press secretary Jen Psaki said in a statement.

“The White House will add a high-level liaison between Asia Pacific islanders that will ensure that the community’s voice is further represented and heard,” said Psaki.

Senator Mazie Hirono attends a Senate Judicial Committee hearing for Christine Blasey Ford to testify on allegations of sexual assault against Supreme Court candidate Brett M. Kavanaugh on Capitol Hill in Washington, United States, on September 27, 2018 .

Erin Schaff | Reuters

A day earlier, Duckworth criticized the government for not appointing “a single AAPI” official to a cabinet position.

“That’s not acceptable. I told the White House that,” said Duckworth, the first Thai American to be elected to Congress.

Duckworth said Tuesday that “until they find out,” she would “vote no on anything but the diversity contenders”.

Hirono joined Duckworth’s protest Tuesday evening, telling reporters they are demanding “a pledge from the White House that there will be greater representation of diversity in the cabinet and senior positions of the White House.”

Until then, Hirono said she would join Duckworth in “voting no to non-diversity nominees”.

But Hirono reversed course that night after posting initial reports on the new AAPI liaison role.

“I had a productive conversation with the White House today to clarify my perspective on the importance of diversity in the president’s cabinet,” Hirono tweeted.

“Based on the private conversation we have had, I will continue to vote to endorse the historic and highly qualified candidates that President Biden has appointed to his administration.”

Duckworth backed off her threat too.

The senator “appreciates the assurances made by the Biden administration that it will do much more to improve the voices and prospects of the AAPI at the highest levels of government,” spokesman Ben Garmisa said in a statement.

“Accordingly, it will not stand in the way of President Biden’s qualified candidates – including more AAPI leaders,” the statement said.

Program Notice: CNBC’s “Race & Opportunity in America: The Asian-American Experience” will air on Wednesday, March 31st at 8:00 pm CET.

Categories
Business

AstraZeneca missteps threaten to additional erode belief as firm seeks U.S. approval

AstraZeneca missteps threaten to further erode trust as company seeks U.S. approval

A medical syringe and vial in front of the logo of UK biopharmaceutical company AstraZeneca in this illustrative photo taken on November 18, 2020.

STR | NurPhoto | Getty Images

U.S. health officials released a bizarre statement early Tuesday that AstraZeneca may have based the results of its Covid-19 vaccine study on outdated information.

The company’s fumbling was just the latest “self-inflicted wound” in a series of missteps that threaten to undermine public confidence in his shot, public health and vaccine experts told CNBC.

On Monday, AstraZeneca announced the long-awaited results of its Phase 3 clinical trial of the Covid-19 vaccine it was developing at Oxford University. It is 79% effective in preventing symptomatic diseases and 100% effective against serious illness and hospitalization. According to the company, the analysis was based on 32,449 participants in 88 test centers in the USA, Peru and Chile.

Results questioned

The National Institute of Allergy and Infectious Diseases questioned the accuracy of these results early Tuesday when it was informed by the data and safety oversight body overseeing the study that the UK-based company may have information in the results of its U.S. Vaccine studies included that have provided an “incomplete view of efficacy data”.

“We urge the company to work with the DSMB to review efficacy data and ensure that the most accurate and up-to-date efficacy data is released as soon as possible,” said a NIAID statement.

NIAID director Dr. Anthony Fauci said the DSMB, an independent group of experts overseeing clinical trials in the United States, has raised concerns with the agency that the results in AstraZeneca’s press release are more favorable than more recent data from the vaccine study showed, according to STAT News. “I was kind of stunned,” Fauci told STAT, The agency could not be silent.

Unusual statement

The statement by NIAID, which is part of the National Institutes of Health, is highly unusual, health experts said. The last time a US agency statement caused a stir was in September when one of its panels said there was “insufficient data” to show convalescent plasma work against the coronavirus, in line with claims made at the time FDA Commissioner Dr. Stephen Hahn disagreed.

AstraZeneca’s data hiccup is just the latest example in a series of mistakes the company has made that could affect people’s willingness to take the vaccine, which may be approved as early as next month in the U.S., said Isaac Bogoch, an infectious disease expert sat on numerous data and security oversight bodies.

The problems first started in September after the company failed to promptly inform Food and Drug Administration officials that it called off its trial worldwide after a study participant fell ill, according to the New York Times. The company would face other issues later, including criticism, after volunteers were given incorrect vaccine doses in its studies and countries asked if its vaccine was suitable for use in people over 65. Most recently, countries suspended the use of the shot after reports of temporary blood clots in some vaccinated people.

Avoidable defects

“This has been an endless roller coaster ride of what I might call preventable communications mistakes,” Bogoch told CNBC. “You have to be open, you have to be honest, you have to be transparent. That includes both the good and the bad news.”

Bogoch said the missteps were not good for public confidence in the vaccine, adding: “We are already dealing with issues of public confidence in the launch of the vaccine [overall] and one must have public trust to have a successful public health initiative. “

Dr. Leana Wen, professor of public health at George Washington University and former Baltimore health commissioner, said AstraZeneca’s recent hiccups could damage not only public confidence in the company’s vaccine, but confidence in all of its Covid-19 vaccines .

“At this point it is really important that there is full transparency. We need to know what happened. Why does there seem to be this discrepancy in the data?” Said Wen. “I don’t remember seeing public disagreements like this one. And that is again throwing red flags at a time when we can least afford it.”

‘Be assured’

During an interview on CNN Tuesday, Andy Slavitt, President Joe Biden’s senior advisor on the pandemic, tried to reassure Americans about the vaccines. He said, “The public should be confident that nothing will be approved unless the FDA thoroughly analyzes it.” Data.”

When the AstraZeneca vaccine is reviewed by the FDA, the agency will “judge what the data says or what it says and whether or not it is approved. Until then, this is all just stuff that will do it.” happen in the background, “said Slavitt.” We believe this transparency and scientific independence are critical to public trust.

While Americans may not trust the vaccine, the data debacle is unlikely to affect the FDA’s review of the shot once the company submits it for emergency approval, said Lawrence Gostin, a law professor and director of the Collaborating Center on National and International the World Health Organization Global Health Act.

Pivot

“It certainly doesn’t help if the NIH rebukes you shortly before the application for approval,” Gostin said, adding that the number of “self-inflicted wounds” the company had “was astounding.” “AstraZeneca has a good and safe vaccine that I think will help vaccinate America and the world.”

Dr. William Schaffner, an epidemiologist who previously sat on two data security supervisory boards for staphylococcal vaccines, said the eventual FDA approval will be critical not only for the US but for other countries as well, as AstraZeneca’s vaccine is cheaper and easier to sell than its competitors.

“That would resonate around the world and give other health ministries confidence in this vaccine,” said Schaffner.

Correction: This story has been updated to correct the AstraZeneca vaccine dosing regimen. It requires two doses.